Jinhua Huang – Trademark Portfolio

Entity Type: 01

Jinhua Huang holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 18 (Leather Goods) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include FLEVIET and ARRASRGI. The owner is based in Shenzhen, Guangdong.

Room 302, Building A2, No. 1, Yufu Lane

Jian'an 1st Road, Baocheng District

Shenzhen, Guangdong 518000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ARRASRGI
ARRASRGI
Registered 2025
FLEVIET
FLEVIET
Registered 2025

Trademark Classifications

Jinhua Huang's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

18
Leather Goods (1 filing)

Leather and imitations of leather; animal skins, hides; trunks and travelling bags

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Jinhua Huang have?

Jinhua Huang has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Jinhua Huang file in?

Jinhua Huang files trademarks across 2 Nice Classification classes. The most active classes are Class 18 (Leather Goods), Class 10 (Medical Apparatus). Class 18 covers leather and imitations of leather; animal skins, hides; trunks and travelling bags.

What are Jinhua Huang's most well-known trademarks?

Jinhua Huang's registered trademark portfolio includes well-known marks such as FLEVIET and ARRASRGI. These are among 2 currently registered trademarks in the portfolio.

What is Jinhua Huang's trademark registration success rate?

Jinhua Huang has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.